NJ-RAHWAY Efinopegdutide (MK-6024), an investigational GLP-1/glucagon receptor co-agonist, has new findings that have been accepted for oral presentation at the European Association for the Study of the Liver (EASL) Annual Congress from June 21–24, according to Merck, also known as MSD outside of North America and Canada. Results from the Phase 2a clinical trial investigating Efinopegdutide in adult patients with nonalcoholic fatty liver disease (NAFLD) are among the information to be disclosed.
Separately, the US Food and Drug Administration (FDA) recently approved Efinopegdutide Fast Track Designation as a possible therapy for patients with nonalcoholic steatohepatitis (NASH), a more severe type of NAFLD that involves liver inflammation and damage. Fast Track is a procedure created to speed up the development of drug candidates and their review in order to cure critical illnesses and meet unmet medical needs. There are no authorized treatments for NASH at the moment.
“We are looking forward to sharing detailed findings from the Phase IIa study of Efinopegdutide with the scientific community at the EASL Congress,” said Sam Engel, associate vice president, global clinical development, Merck Research Laboratories.
“Significant patient need remains for new treatment options for NASH. These compelling data in patients with NAFLD, along with the recent receipt of Fast Track Designation from the FDA, provide strong rationale for advancing Efinopegdutide into Phase 2b development for patients with NASH.”